{"id":"atropine","rwe":[],"_fda":{"id":"100be173-227f-a802-e063-6294a90ae92e","set_id":"0060b971-19bd-2849-e063-6294a90afca8","openfda":{"unii":["03J5ZE7KA5"],"route":["INTRAVENOUS"],"rxcui":["1190795"],"spl_id":["100be173-227f-a802-e063-6294a90ae92e"],"brand_name":["ATROPINE SULFATE"],"spl_set_id":["0060b971-19bd-2849-e063-6294a90afca8"],"package_ndc":["51662-1626-1","51662-1626-2","51662-1626-3"],"product_ndc":["51662-1626"],"generic_name":["ATROPINE SULFATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ATROPINE SULFATE"],"manufacturer_name":["HF Acquisition Co LLC, DBA HealthFirst"],"application_number":["ANDA216120"],"original_packager_product_ndc":["0517-1001"]},"version":"4","overdosage":["10 OVERDOSAGE Excessive dosing may cause palpitation, dilated pupils, difficulty in swallowing, hot dry skin, thirst, dizziness, restlessness, tremor, fatigue and ataxia. Toxic doses lead to restlessness and excitement, hallucinations, delirium and coma. Depression and circulatory collapse occur only with severe intoxication. In such cases, blood pressure declines and death due to respiratory failure may ensue following paralysis and coma. The fatal adult dose of atropine is not known. In pediatric populations, 10 mg or less may be fatal. In the event of toxic overdosage, a short acting barbiturate or diazepam may be given as needed to control marked excitement and convulsions. Large doses for sedation should be avoided because central depressant action may coincide with the depression occurring late in atropine poisoning. Central stimulants are not recommended. Physostigmine, given as an atropine antidote by slow intravenous injection of 1 to 4 mg (0.5 to 1 mg in pediatric populations), rapidly abolishes delirium and coma caused by large doses of atropine. Since physostigmine is rapidly destroyed, the patient may again lapse into coma after one to two hours, and repeated doses may be required. Artificial respiration with oxygen may be necessary. Ice bags and alcohol sponges help to reduce fever, especially in pediatric populations. Atropine is not removed by dialysis."],"description":["11 DESCRIPTION Atropine Sulfate Injection, USP is a sterile, nonpyrogenic isotonic solution of atropine sulfate monohydrate in water for injection with sodium chloride sufficient to render the solution isotonic. It is administered parenterally by intravenous injection. Each milliliter (mL) contains 0.4 mg or 1 mg of atropine sulfate monohydrate equivalent to 0.332 mg or 0.83 mg of atropine, and sodium chloride, 9 mg. May contain sodium hydroxide and/or sulfuric acid for pH adjustment. 0.308 mOsmol/mL (calc.). pH (3.0 to 5.0). The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and is intended for use only as a single-dose injection. When smaller doses are required the unused portion should be discarded. Atropine Sulfate, USP is chemically designated 1α H, 5α H-Tropan-3-α-ol (±)-tropate (ester), sulfate (2:1) (salt) monohydrate, (C17H23NO3)2 ∙ H2SO4 ∙ H2O, colorless crystals or white crystalline powder very soluble in water. It has the following structural formula: Atropine, a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and 1-hyocyamine, whose activity is due almost entirely to the levo isomer of the drug. STRUCTURE"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Atropine Sulfate Injection, USP 1 mg/mL is supplied in 1 mL, single-dose glass vial. NDC 51662-1626-1 ATROPINE SULFATE INJECTION, USP 1mg/mL 1mL VIAL Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C and 30°C (59°F and 86°F). [See USP Controlled Room Temperature.] HF Acquisition Co LLC, DBA HealthFirst 11629 49th Pl W. Mukilteo, WA 98275"],"effective_time":"20240128","adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of atropine sulfate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Most of the side effects of atropine are directly related to its antimuscarinic action. Dryness of the mouth, blurred vision, photophobia and tachycardia commonly occur. Anhidrosis can produce heat intolerance. Constipation and difficulty in micturition may occur in elderly patients. Occasional hypersensitivity reactions have been observed, especially skin rashes which in some instances progressed to exfoliation."],"contraindications":["4 CONTRAINDICATIONS None."],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Mexiletine Atropine Sulfate Injection decreased the rate of mexiletine absorption without altering the relative oral bioavailability; this delay in mexiletine absorption was reversed by the combination of atropine and intravenous metoclopramide during pretreatment for anesthesia."],"recent_major_changes":[""],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Atropine is an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and other choline esters. Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine, but this occurs less readily than with responses to injected (exogenous) choline esters. 12.2 Pharmacodynamics Atropine-induced parasympathetic inhibition may be preceded by a transient phase of stimulation, especially on the heart where small doses first slow the rate before characteristic tachycardia develops due to paralysis of vagal control. Atropine exerts a more potent and prolonged effect on heart, intestine and bronchial muscle than scopolamine, but its action on the iris, ciliary body and certain secretory glands is weaker than that of scopolamine. Unlike the latter, atropine in clinical doses does not depress the central nervous system but may stimulate the medulla and higher cerebral centers. Although mild vagal excitation occurs, the increased respiratory rate and (sometimes) increased depth of respiration produced by atropine are more probably the result of bronchiolar dilatation. Accordingly, atropine is an unreliable respiratory stimulant and large or repeated doses may depress respiration. Adequate doses of atropine abolish various types of reflex vagal cardiac slowing or asystole. The drug also prevents or abolishes bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine also may lessen the degree of partial heart block when vagal activity is an etiologic factor. In some patients with complete heart block, the idioventricular rate may be accelerated by atropine; in others, the rate is stabilized. Occasionally a large dose may cause atrioventricular (A-V) block and nodal rhythm. Atropine Sulfate Injection, USP in clinical doses counteracts the peripheral dilatation and abrupt decrease in blood pressure produced by choline esters. However, when given by itself, atropine does not exert a striking or uniform effect on blood vessels or blood pressure. Systemic doses slightly raise systolic and lower diastolic pressures and can produce significant postural hypotension. Such doses also slightly increase cardiac output and decrease central venous pressure. Occasionally, therapeutic doses dilate cutaneous blood vessels, particularly in the \"blush\" area (atropine flush), and may cause atropine \"fever\" due to suppression of sweat gland activity in infants and small children. The effects of intravenous atropine on heart rate (maximum heart rate) and saliva flow (minimum flow) after intravenous administration (rapid, constant infusion over 3 min.) are delayed by 7 to 8 minutes after drug administration and both effects are non-linearly related to the amount of drug in the peripheral compartment. Changes in plasma atropine levels following intramuscular administration (0.5 to 4 mg doses) and heart rate are closely overlapped but the time course of the changes in atropine levels and behavioral impairment indicates that pharmacokinetics is not the primary rate-limiting mechanism for the central nervous system effect of atropine. 12.3 Pharmacokinetics Atropine disappears rapidly from the blood following injection and is distributed throughout the body. Exercise, both prior to and immediately following intramuscular administration of atropine, significantly increases the absorption of atropine due to increased perfusion in the muscle and significantly decreases the clearance of atropine. The pharmacokinetics of atropine is nonlinear after intravenous administration of 0.5 to 4 mg. Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range. Atropine readily crosses the placental barrier and enters the fetal circulation, but is not found in amniotic fluid. Much of the drug is destroyed by enzymatic hydrolysis, particularly in the liver; from 13 to 50% is excreted unchanged in the urine. Traces are found in various secretions, including milk. The major metabolites of atropine are noratropine, atropin-n-oxide, tropine, and tropic acid. The metabolism of atropine is inhibited by organophosphate pesticides. Specific Populations The elimination half-life of atropine is more than doubled in children under two years and the elderly (>65 years old) compared to other age groups. There is no gender effect on the pharmacokinetics and pharmacodynamics (heart rate changes) of atropine."],"indications_and_usage":["1 INDICATIONS & USAGE Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS 5.1 Tachycardia When the recurrent use of atropine is essential in patients with coronary artery disease, the total dose should be restricted to 2 to 3 mg (maximum 0.03 to 0.04 mg/kg) to avoid the detrimental effects of atropine-induced tachycardia on myocardial oxygen demand. 5.2 Acute Glaucoma Atropine may precipitate acute glaucoma. 5.3 Pyloric Obstruction Atropine may convert partial organic pyloric stenosis into complete obstruction. 5.4 Complete Urinary Retention Atropine may lead to complete urinary retention in patients with prostatic hypertrophy. 5.5 Viscid Plugs Atropine may cause inspissation of bronchial secretions and formation of viscid plugs in patients with chronic lung disease."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed to evaluate the carcinogenic or mutagenic potential of atropine or its potential to affect fertility adversely."],"spl_unclassified_section":["HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ATROPINE SULFATE INJECTION safely and effectively. See full prescribing information for ATROPINE SULFATE INJECTION. ATROPINE SULFATE INJECTION, for intravenous use Initial U.S. Approval: 1960 INDICATIONS AND USAGE Atropine is a muscarinic antagonist indicated for temporary blockade of severe or life threatening muscarinic effects. ( 1 ) DOSAGE AND ADMINISTRATION For intravenous administration. ( 2 ). Titrate according to heart rate, PR interval, blood pressure and symptoms. ( 2 ) Adult dosage Antisialagogue or for antivagal effects: Initial single dose of 0.5 to 1 mg. ( 2 ) Antidote for organophosphorus or muscarinic mushroom poisoning: Initial single dose of 2 to 3 mg, repeated every 20 to 30 minutes. ( 2 ) Bradyasystolic cardiac arrest: 1 mg dose, repeated every 3 to 5 minutes if asystole persists. ( 2 ) Patients with Coronary Artery Disease: Limit the total dose to 0.03 mg/kg to 0.04 mg/kg. ( 2 ) DOSAGE FORMS AND STRENGTHS Injection: 0.4 or 1 mg/mL as a clear, colorless solution in a single-dose vial. ( 3 ) CONTRAINDICATIONS None. ( 4 ) WARNINGS AND PRECAUTIONS Tachycardia ( 5 ) Glaucoma ( 5 ) Pyloric obstruction ( 5 ) Worsening urinary retention ( 5 ) Viscid bronchial plugs ( 5 ) ADVERSE REACTIONS Most adverse reactions are directly related to atropine's antimuscarinic action. Dryness of the mouth, blurred vision, photophobia and tachycardia commonly occur with chronic administration of therapeutic doses. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact American Regent, Inc. at 1-800-734-9236, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONS Mexiletine: Decreases rate of mexiletine absorption. ( 7 ) Revised: 9/2021","TABLE OF CONTENTS FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 General Administration 2.2 Adult Dosage 2.3 Pediatric Dosage 2.4 Dosing in Patients with Coronary Artery Disease 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Tachycardia 5.2 Acute Glaucoma 5.3 Pyloric Obstruction 5.4 Complete Urinary Retention 5.5 Viscid Plugs 6 ADVERSE REACTIONS 7 DRUG INTERACTIONS 7.1 Mexiletine 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 16 HOW SUPPLIED/STORAGE AND HANDLING * Sections or subsections omitted from the full prescribing information are not listed."],"dosage_and_administration":["2 DOSAGE & ADMINISTRATION 2.1 General Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer unless solution is clear and seal is intact. Each vial is intended for single dose only. Discard unused portion. For Intravenous administration. Titrate based on heart rate, PR interval, blood pressure and symptoms. 2.2 Adult Dosage 2.3 Pediatric Dosage Dosing in pediatric populations has not been well studied. Usual initial dose is 0.01 to 0.03 mg/kg. 2.4 Dosing in Patients with Coronary Artery Disease Limit the total dose of atropine sulfate to 0.03 to 0.04 mg/kg [see WARNINGS AND PRECAUTIONS (5.1 )]. DOSAGE"],"spl_product_data_elements":["ATROPINE SULFATE ATROPINE SULFATE SULFURIC ACID ATROPINE SULFATE ATROPINE SODIUM HYDROXIDE SODIUM CHLORIDE WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORM & STRENGTH Injection: supplied as a clear, colorless solution in a 1 mL glass vial in the following concentrations: 0.4 mg/mL: containing 0.4 mg of atropine sulfate monohydrate equivalent to 0.332 mg of atropine. 1 mg/mL: containing 1 mg atropine sulfate monohydrate equivalent to 0.83 mg of atropine."],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATION 8.1 Pregnancy Pregnancy Risk Summary There are risks to the mother and fetus associated with untreated severe or life-threatening muscarinic events (see Clinical Considerations). Available data from published observational studies on atropine use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Animal reproduction studies have not been conducted with atropine. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Severe or life-threatening muscarinic events such as acute organophosphate poisoning and symptomatic bradycardia are medical emergencies in pregnancy which can be fatal if left untreated. Life-sustaining therapy for the pregnant woman should not be withheld because of concerns regarding the effects of atropine on the fetus. Data Human Data Atropine crosses the placenta [see Clinical Pharmacology (12.3) ]. No adequate and well-controlled studies are available regarding use of atropine in pregnant women. In a cohort study of 401 pregnancies in the first trimester and 797 pregnancies in the second or third trimester, atropine use was not associated with an increased risk of congenital malformation. In a surveillance study, 381 newborns were exposed to atropine during the first trimester; 18 major birth defects were observed when 16 were expected. No specific pattern of major birth defects was identified. In another surveillance study of 50 pregnancies in the first trimester, atropine use was not associated with an increased risk of malformations. Methodological limitations of these observational studies including the inability to control for the dosage and timing of atropine exposure, underlying maternal disease, or concomitant maternal drug use, cannot definitively establish or exclude any drug associated risk during pregnancy. 8.2 Lactation Risk Summary Trace amounts of atropine have been reported in human milk after oral intake. There are no available data on atropine levels in human milk after intravenous injection, the effects on the breastfed infant, or the effects on milk production. Clinical Considerations Minimizing exposure The elimination half-life of atropine is more than doubled in children less than 2 years of age [SEE CLINICAL PHARMACOLOGY (12.3)]. To minimize potential infant exposure to Atropine Sulfate Injection, a woman may pump and discard her milk for 24 hours after use before resuming to breastfeed her infant. 8.4 Pediatric Use Recommendations for use in pediatric patients are not based on clinical trials. 8.5 Geriatric Use An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 51662-1626-1 - ATROPINE SULFATE INJECTION, USP 1mg/mL 1mL VIAL NDC 51662-1626-1 SERIALIZED LABELING VIAL LABEL RFID Label VIAL","PRINCIPAL DISPLAY PANEL, POUCH LABEL 51662-1626-2 Pouch Label Pouch label","PRINCIPAL DISPLAY PANEL, CASE LABEL 51662-1626-3 CASE LABEL Case Label RFID LABEL"]},"tags":[{"label":"Anticholinergic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Muscarinic acetylcholine receptor M3","category":"target"},{"label":"CHRM3","category":"gene"},{"label":"CHRM4","category":"gene"},{"label":"CHRM1","category":"gene"},{"label":"A03BA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intramuscular","category":"route"},{"label":"Endotracheal","category":"route"},{"label":"Elixir","category":"form"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Perioperative Mydriasis","category":"indication"},{"label":"Mmt","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Adjuvants, Anesthesia","category":"pharmacology"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Bronchodilator Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Muscarinic Antagonists","category":"pharmacology"},{"label":"Mydriatics","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":220.855,"date":"","count":773,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 773 times (LLR=221)"},{"llr":203.374,"date":"","count":98,"signal":"Stress cardiomyopathy","source":"DrugCentral FAERS","actionTaken":"Reported 98 times (LLR=203)"},{"llr":168.975,"date":"","count":253,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 253 times (LLR=169)"},{"llr":164.136,"date":"","count":139,"signal":"Therapy interrupted","source":"DrugCentral FAERS","actionTaken":"Reported 139 times (LLR=164)"},{"llr":156.376,"date":"","count":276,"signal":"Cardiac arrest","source":"DrugCentral FAERS","actionTaken":"Reported 276 times (LLR=156)"},{"llr":136.661,"date":"","count":105,"signal":"Macular degeneration","source":"DrugCentral FAERS","actionTaken":"Reported 105 times (LLR=137)"},{"llr":130.82,"date":"","count":54,"signal":"Anticholinergic syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 54 times (LLR=131)"},{"llr":121.234,"date":"","count":327,"signal":"Dehydration","source":"DrugCentral FAERS","actionTaken":"Reported 327 times (LLR=121)"},{"llr":104.529,"date":"","count":439,"signal":"Hypotension","source":"DrugCentral FAERS","actionTaken":"Reported 439 times (LLR=105)"},{"llr":97.105,"date":"","count":40,"signal":"Hyperthermia malignant","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=97)"},{"llr":95.426,"date":"","count":774,"signal":"Diarrhoea","source":"DrugCentral FAERS","actionTaken":"Reported 774 times (LLR=95)"},{"llr":95.026,"date":"","count":106,"signal":"Therapy cessation","source":"DrugCentral FAERS","actionTaken":"Reported 106 times (LLR=95)"},{"llr":93.327,"date":"","count":72,"signal":"Hyperthermia","source":"DrugCentral FAERS","actionTaken":"Reported 72 times (LLR=93)"},{"llr":91.915,"date":"","count":107,"signal":"Arthralgia","source":"DrugCentral FAERS","actionTaken":"Reported 107 times (LLR=92)"},{"llr":90.786,"date":"","count":24,"signal":"Drug intolerance","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=91)"}],"drugInteractions":[{"url":"/drug/cisapride","drug":"cisapride","action":"Monitor closely","effect":"May interact with Cisapride","source":"DrugCentral","drugSlug":"cisapride"},{"url":"/drug/pramlintide","drug":"pramlintide","action":"Avoid combination","effect":"May interact with Pramlintide","source":"DrugCentral","drugSlug":"pramlintide"}],"commonSideEffects":[{"effect":"Anaphylaxis","drugRate":"reported","severity":"serious"},{"effect":"Urticaria","drugRate":"reported","severity":"serious"},{"effect":"Dermatologic manifestations","drugRate":"reported","severity":"serious"},{"effect":"Parasympathetic paralysis","drugRate":"reported","severity":"serious"},{"effect":"Cycloplegia","drugRate":"reported","severity":"serious"},{"effect":"Increased intraocular pressure","drugRate":"reported","severity":"serious"},{"effect":"Gastroesophageal reflux","drugRate":"reported","severity":"mild"},{"effect":"Paralytic ileus","drugRate":"reported","severity":"serious"},{"effect":"Bradycardia","drugRate":"reported","severity":"serious"},{"effect":"Tachycardia","drugRate":"reported","severity":"serious"},{"effect":"Palpitations","drugRate":"reported","severity":"mild"},{"effect":"Nervousness","drugRate":"reported","severity":"mild"},{"effect":"Drowsiness","drugRate":"reported","severity":"mild"},{"effect":"Weakness","drugRate":"reported","severity":"mild"},{"effect":"Dizziness","drugRate":"reported","severity":"mild"},{"effect":"Insomnia","drugRate":"reported","severity":"mild"},{"effect":"Fever","drugRate":"reported","severity":"mild"},{"effect":"Mental confusion","drugRate":"reported","severity":"serious"},{"effect":"CNS stimulation","drugRate":"reported","severity":"serious"},{"effect":"Restlessness","drugRate":"reported","severity":"mild"},{"effect":"Tremor","drugRate":"reported","severity":"mild"},{"effect":"Xerostomia","drugRate":"reported","severity":"mild"},{"effect":"Altered taste perception","drugRate":"reported","severity":"mild"},{"effect":"Nausea","drugRate":"reported","severity":"mild"},{"effect":"Vomiting","drugRate":"reported","severity":"mild"},{"effect":"Dysphagia","drugRate":"reported","severity":"mild"},{"effect":"Heartburn","drugRate":"reported","severity":"mild"},{"effect":"Constipation","drugRate":"reported","severity":"mild"},{"effect":"Bloating","drugRate":"reported","severity":"mild"},{"effect":"Urinary hesitancy and retention","drugRate":"reported","severity":"serious"},{"effect":"Impotence","drugRate":"reported","severity":"serious"},{"effect":"Blurred vision","drugRate":"reported","severity":"serious"},{"effect":"Mydriasis","drugRate":"reported","severity":"serious"},{"effect":"Photophobia","drugRate":"reported","severity":"serious"},{"effect":"Headache","drugRate":"reported","severity":"mild"},{"effect":"Flushing","drugRate":"reported","severity":"mild"},{"effect":"Suppression of lactation","drugRate":"reported","severity":"mild"},{"effect":"Nasal congestion","drugRate":"reported","severity":"mild"},{"effect":"Decreased sweating","drugRate":"reported","severity":"mild"}],"specialPopulations":{"Pregnancy":"Use during pregnancy only if clearly needed. Reproduction studies performed in mice revealed no evidence of impaired fertility or harm to the fetus due to atropine.","Geriatric use":"Elderly patients may react with symptoms of excitement, agitation, drowsiness, and other untoward manifestations to even small doses of the drug. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range.","Paediatric use":"The safety and effectiveness of diphenoxylate hydrochloride and atropine sulfate tablets have been established in pediatric patients 13 years of age and older. Contraindicated in pediatric patients less than 13 years of age.","Hepatic impairment":"Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function"}},"trials":[],"aliases":[],"company":"Mmt","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$7.1821/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,586","description":"ATROPINE 1% EYE DROPS","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ATROPINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:21:02.811850+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:21:09.541573+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ATROPINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:21:09.879518+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:01.693499+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:01.693523+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4557433/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:21:10.692531+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA216120","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:21:01.693527+00:00"}},"allNames":"enlon-plus","offLabel":[],"synonyms":["atropine","(+/-)-Atropine","atropin","atropinum sulphuricum","DL-Hyoscyamine","tropine tropate","atropine sulfate"],"timeline":[{"date":"1960-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GD SEARLE LLC to Mmt"},{"date":"1960-09-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Gd Searle Llc)"},{"date":"1987-01-30","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"},{"date":"2018-07-09","type":"positive","source":"FDA Orange Book","milestone":"Atropine (Autoinjector) approved — EQ 2MG SULFATE/0.7ML (EQ 2MG SULFATE/0.7ML)"}],"aiSummary":"Enlon-Plus (ATROPINE) is a small molecule anticholinergic drug developed by GD SEARLE LLC and currently owned by Mmt. It targets the muscarinic acetylcholine receptor M3 and is used to treat perioperative mydriasis. Enlon-Plus is off-patent and has a generic manufacturer. The drug has a half-life of 4.1 hours and bioavailability of 50%. It was FDA approved in 1960.","brandName":"Enlon-Plus","ecosystem":[{"indication":"Perioperative Mydriasis","otherDrugs":[{"name":"cyclopentolate","slug":"cyclopentolate","company":"Alcon Labs Inc"},{"name":"homatropine","slug":"homatropine","company":""},{"name":"scopolamine","slug":"scopolamine","company":"Novartis"},{"name":"tropicamide","slug":"tropicamide","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Muscarinic acetylcholine receptor M3","novelty":"Follow-on","targets":[{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"SLC22A1","source":"DrugCentral","target":"Solute carrier family 22 member 1","protein":"Solute carrier family 22 member 1"}],"moaClass":"Cholinergic Antagonists","modality":"Small Molecule","drugClass":"Anticholinergic","explanation":"","oneSentence":"","technicalDetail":"Enlon-Plus (ATROPINE) is a competitive antagonist of the muscarinic acetylcholine receptor M3, inhibiting the parasympathetic nervous system's effect on the eye and causing mydriasis."},"commercial":{"launchDate":"1960","_launchSource":"DrugCentral (FDA 1960-09-15, GD SEARLE LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/260","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ATROPINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ATROPINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:51:33.666483","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:21:14.102954+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"amfetamine","drugSlug":"amfetamine","fdaApproval":"1955-09-09","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amisulpride","drugSlug":"amisulpride","fdaApproval":"2020-02-26","patentExpiry":"Mar 10, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitraz","drugSlug":"amitraz","fdaApproval":"","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amlodipine","drugSlug":"amlodipine","fdaApproval":"1992-07-31","patentExpiry":"Feb 24, 2041","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"apomorphine","drugSlug":"apomorphine","fdaApproval":"2004-04-20","patentExpiry":"Jun 11, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"apraclonidine","drugSlug":"apraclonidine","fdaApproval":"1987-12-31","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"atropine","indications":{"approved":[{"name":"Perioperative Mydriasis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"No patient eligibility criteria specified"}],"offLabel":[],"pipeline":[]},"currentOwner":"Mmt","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"amfetamine","brandName":"amfetamine","genericName":"amfetamine","approvalYear":"1955","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amisulpride","brandName":"amisulpride","genericName":"amisulpride","approvalYear":"2020","relationship":"same-target"},{"drugId":"amitraz","brandName":"amitraz","genericName":"amitraz","approvalYear":"","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amlodipine","brandName":"amlodipine","genericName":"amlodipine","approvalYear":"1992","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"apomorphine","brandName":"apomorphine","genericName":"apomorphine","approvalYear":"2004","relationship":"same-target"},{"drugId":"apraclonidine","brandName":"apraclonidine","genericName":"apraclonidine","approvalYear":"1987","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07309393","phase":"NA","title":"Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-12-31","conditions":["Residual Neuromuscular Block"],"enrollment":240,"completionDate":"2026-06-30"},{"nctId":"NCT07494799","phase":"","title":"Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2026-04-01","conditions":["Progressive Myopia, Pediatric Myopia, Orthokeratology-related Myopia Progression"],"enrollment":3890,"completionDate":"2027-04-01"},{"nctId":"NCT05065424","phase":"PHASE4","title":"Premedication for Less Invasive Surfactant Administration Study (PRELISA)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-04-06","conditions":["Respiratory Distress Syndrome, Newborn"],"enrollment":58,"completionDate":"2026-03-02"},{"nctId":"NCT07475585","phase":"NA","title":"Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve","status":"NOT_YET_RECRUITING","sponsor":"Fangbiao Tao","startDate":"2026-03-30","conditions":["Myopia","Ear Acupressure Pellets","Hyperopia Reserve","Low-concentration Atropine Eye Drops","Eye Axis"],"enrollment":380,"completionDate":"2027-07-30"},{"nctId":"NCT04699357","phase":"NA","title":"The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial","status":"COMPLETED","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2021-07-04","conditions":["High Myopia"],"enrollment":219,"completionDate":"2024-09-01"},{"nctId":"NCT07268586","phase":"PHASE4","title":"Intravenous Atropine in Reducing Reperfusion Arrhythmias, Conduction Abnormalities and Hypotension in Inferior ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2025-08-01","conditions":["Myocardial Infarction"],"enrollment":158,"completionDate":"2026-02-28"},{"nctId":"NCT02858310","phase":"PHASE1,PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":["Papillomavirus Infections","Cervical Intraepithelial Neoplasia","Carcinoma In Situ","Vulvar Neoplasms","Vulvar Diseases"],"enrollment":224,"completionDate":"2025-07-02"},{"nctId":"NCT07456488","phase":"PHASE2","title":"The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group","status":"RECRUITING","sponsor":"Liaquat National Hospital & Medical College","startDate":"2025-07-13","conditions":["Focus on Axial Length"],"enrollment":60,"completionDate":"2026-04-30"},{"nctId":"NCT07449247","phase":"PHASE1,PHASE2","title":"PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2026-03-30","conditions":["Pre-myopia"],"enrollment":233,"completionDate":"2027-06-30"},{"nctId":"NCT07095894","phase":"PHASE3","title":"A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control","status":"NOT_YET_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2026-03-01","conditions":["Myopia"],"enrollment":348,"completionDate":"2029-06-01"},{"nctId":"NCT07148596","phase":"","title":"Changes of Ciprofol Dosage and Bispectral Index Required for Loss of Consciousness in Patients of Different Ages","status":"COMPLETED","sponsor":"General Hospital of Ningxia Medical University","startDate":"2025-09-01","conditions":["Ciprofol"],"enrollment":125,"completionDate":"2025-12-07"},{"nctId":"NCT04923841","phase":"NA","title":"Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2021-09-09","conditions":["Myopia"],"enrollment":579,"completionDate":"2026-12-31"},{"nctId":"NCT06358755","phase":"NA","title":"Combination Effect of Optical Defocus and Low Dose Atropine in Myopia Control","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2024-07-12","conditions":["Myopia"],"enrollment":112,"completionDate":"2027-01-31"},{"nctId":"NCT07434635","phase":"PHASE4","title":"APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":["Eye Disorders"],"enrollment":62,"completionDate":"2029-02"},{"nctId":"NCT07409935","phase":"PHASE4","title":"A Comparative Study Between Combination of Propofol and Dexmedetomidine Versus Propofol Alone in Anesthesia for Rigid Bronchoscopy by Using the Patient State Index Monitor","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-04-01","conditions":["Patients Undergoing Rigid Bronchoscopy"],"enrollment":50,"completionDate":"2025-10-01"},{"nctId":"NCT07406399","phase":"PHASE4","title":"Low Concentration Atropine Combined With Soft Contact Lens in Controlling Myopia Progression in Children With High Myopia","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2023-06-30","conditions":["High Myopia","Low Concentration Atropine","Soft Contact Lens","Children"],"enrollment":120,"completionDate":"2026-01-30"},{"nctId":"NCT07028827","phase":"PHASE3","title":"Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)","status":"RECRUITING","sponsor":"Ocus Innovation Ireland Limited","startDate":"2025-09-01","conditions":["Myopia"],"enrollment":234,"completionDate":"2027-12-31"},{"nctId":"NCT07394036","phase":"PHASE2","title":"Effect of Ipratropium Bromide on EILO","status":"NOT_YET_RECRUITING","sponsor":"Cook Children's Health Care System","startDate":"2026-03-16","conditions":["Exercise-Induced Laryngeal Obstruction","Dyspnea During Activity"],"enrollment":50,"completionDate":"2029-03-30"},{"nctId":"NCT05470881","phase":"PHASE1","title":"Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2022-08-20","conditions":["Myopia"],"enrollment":29,"completionDate":"2022-12-26"},{"nctId":"NCT06783296","phase":"NA","title":"Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2026-01-01","conditions":["Hypertension","Renal Denervation Therapy"],"enrollment":124,"completionDate":"2028-07-31"},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":["Sarcoma, Alveolar Soft Part"],"enrollment":34,"completionDate":"2026-01-16"},{"nctId":"NCT07367178","phase":"PHASE2","title":"Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07","conditions":["Breast Cancer","Advanced HR+/HER2- Breast Cancer","Advanced Triple-Negative Breast Cancer"],"enrollment":30,"completionDate":"2028-01"},{"nctId":"NCT04766554","phase":"NA","title":"Cerebral Oxygen Saturation Monitoring In Cardiac Surgery (COSMICS)","status":"COMPLETED","sponsor":"Instituto Nacional de Cardiologia de Laranjeiras","startDate":"2021-05-19","conditions":["Cardiac Disease","Cognitive Dysfunction"],"enrollment":326,"completionDate":"2024-08-20"},{"nctId":"NCT06366087","phase":"PHASE1","title":"Sublingual Atropine Bioequivalence by Route of Administration (SABER)","status":"COMPLETED","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-04-15","conditions":["Atropine Bioequivalence"],"enrollment":46,"completionDate":"2024-05-22"},{"nctId":"NCT06450132","phase":"PHASE4","title":"Changes in Eye Shape With Myopia Management Interventions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":["Myopia"],"enrollment":75,"completionDate":"2026-07-31"},{"nctId":"NCT07364370","phase":"NA","title":"Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":["Pediatric Cataract","IOL Implantation","Myopia Progression"],"enrollment":50,"completionDate":"2027-12"},{"nctId":"NCT06579287","phase":"PHASE2","title":"A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunhawk Vision Biotech, Inc.","startDate":"2025-01-22","conditions":["Myopia, Progressive"],"enrollment":140,"completionDate":"2026-12"},{"nctId":"NCT06948409","phase":"","title":"NMBA Reversal and Postoperative Urinary Retention","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2025-06-08","conditions":["Neuromuscular Blocking Agents","Urinary Retention After Procedure","Urinary Retention Postoperative","Neuromuscular Blockade Reversal Agent","Neuromuscular Blockade","Costs","Atropine","Sugammadex","Glycopyrrolate","Neostigmine","Anesthesia"],"enrollment":70000,"completionDate":"2026-06-01"},{"nctId":"NCT07358689","phase":"PHASE2","title":"Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":["NSCLC"],"enrollment":120,"completionDate":"2029-01-01"},{"nctId":"NCT06865677","phase":"PHASE2","title":"Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-09","conditions":["Recurrent Platinum Resistant Epithelial Ovarian Carcinoma","Recurrent Epithelial Endometrial Carcinoma","Recurrent Epithelial Cervical Carcinoma"],"enrollment":2,"completionDate":"2025-07-01"},{"nctId":"NCT05560542","phase":"NA","title":"Intrathecal Dexamethasone and Atropine on Morphine Induced Post-operative Nausea and Vomiting on Caesarean Section","status":"COMPLETED","sponsor":"Assiut University","startDate":"2022-10-01","conditions":["Morphine Adverse Reaction"],"enrollment":150,"completionDate":"2025-10-01"},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":["Nearsightedness","Near Sightedness","Near-sightedness"],"enrollment":852,"completionDate":"2025-05-01"},{"nctId":"NCT07345078","phase":"NA","title":"Study on the Treatment of Post-stroke Dysphagia and Stroke-associated Pneumonia With Bronchoscopy","status":"COMPLETED","sponsor":"The First People's Hospital of Zunyi","startDate":"2019-09-01","conditions":["Stroke Associated Pneumonia","Non Severe Ischemic Stroke","Dysphagia"],"enrollment":50,"completionDate":"2021-09-30"},{"nctId":"NCT07329777","phase":"PHASE3","title":"Atropine in the Treatment of Myopia Study in Malaysia","status":"RECRUITING","sponsor":"IDB VisionCare SDN BHD","startDate":"2025-09-17","conditions":["Myopia Progression"],"enrollment":144,"completionDate":"2029-09"},{"nctId":"NCT05826119","phase":"NA","title":"Intravenous Administration of Magnesium Sulfate in Laparoscopic Hysterectomy Cases","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2024-01-20","conditions":["Laparoscopic Hysterectomy","Magnesium Sulfate","General Anesthesia"],"enrollment":60,"completionDate":"2024-06-15"},{"nctId":"NCT05062031","phase":"NA","title":"Myopia Control in Children: Comparison of Defocus Incorporated Multiple Segments® Lenses Versus Atropine 0.05% Eyedrops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2021-10-19","conditions":["Myopia"],"enrollment":242,"completionDate":"2026-02"},{"nctId":"NCT07271875","phase":"PHASE3","title":"Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-01-01","conditions":["Postoperative Gastrointestinal Dysfunction (POGD)","Postoperative Ileus","Colorectal Surgery"],"enrollment":560,"completionDate":"2027-12-31"},{"nctId":"NCT07253428","phase":"NA","title":"Emergence Agitation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2025-10-30","conditions":["Emergence Agitation","Nasal Surgery"],"enrollment":486,"completionDate":"2026-01-31"},{"nctId":"NCT06449430","phase":"NA","title":"Use of Propofol as a Sedative Agent Versus Spinal Analgesia With Bupivacaine in External Cephalic Version","status":"RECRUITING","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2024-07-06","conditions":["Pregnancy Complications"],"enrollment":270,"completionDate":"2027-11-30"},{"nctId":"NCT04641702","phase":"PHASE4","title":"Comprehensive Esophageal Diagnostics Study","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-03-17","conditions":["Achalasia"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT04903470","phase":"NA","title":"Defecation Patterns in Constipated Patients","status":"RECRUITING","sponsor":"The California Medical Innovations Institute, Inc.","startDate":"2022-12-19","conditions":["Constipation by Outlet Obstruction"],"enrollment":130,"completionDate":"2026-12-30"},{"nctId":"NCT00608725","phase":"NA","title":"Pathophysiology of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1996-12","conditions":["Tachycardia","Postural Orthostatic Tachycardia Syndrome"],"enrollment":260,"completionDate":"2029-12"},{"nctId":"NCT04393103","phase":"PHASE2,PHASE3","title":"Role of Intralipid in Management of Organophosphorus Poisoning","status":"WITHDRAWN","sponsor":"Amani Hassan Abdel-Wahab","startDate":"2024-04-01","conditions":["Organophosphorus Poisoning"],"enrollment":0,"completionDate":"2025-01-01"},{"nctId":"NCT06282848","phase":"NA","title":"Pharmacological and Non-pharmacological Treatment Effects on Children With Different Predicted Myopia Progression Rate","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2024-01-01","conditions":["Myopia"],"enrollment":80,"completionDate":"2026-12"},{"nctId":"NCT07176949","phase":"NA","title":"Early-Onset Myopia Intervention Project","status":"RECRUITING","sponsor":"Shanghai Eye Disease Prevention and Treatment Center","startDate":"2025-06-01","conditions":["Myopia","Pre-myopia"],"enrollment":508,"completionDate":"2028-05-31"},{"nctId":"NCT06431841","phase":"PHASE4","title":"Atropine and Spectacle Combination Treatment (ASPECT): 12-month Results of a Randomized Clinical Trial for Myopia Control","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital San Carlos, Madrid","startDate":"2022-02-23","conditions":["Myopia"],"enrollment":111,"completionDate":"2026-06-30"},{"nctId":"NCT00992901","phase":"EARLY_PHASE1","title":"Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-10","conditions":["Post Bariatricsurgery","Hypoglycemia"],"enrollment":160,"completionDate":"2027-08"},{"nctId":"NCT02823665","phase":"EARLY_PHASE1","title":"The Effects of Bariatric Surgeries on Glucose Metabolism","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2015-07","conditions":["Post Bariatric Surgery","Gastric Bypass","Sleeve Gastrectomy","Hypoglycemia After Gastric Bypass"],"enrollment":200,"completionDate":"2027-08"},{"nctId":"NCT07164092","phase":"PHASE2,PHASE3","title":"Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-09","conditions":["Myopia"],"enrollment":45,"completionDate":"2027-09"},{"nctId":"NCT06523504","phase":"PHASE1,PHASE2","title":"Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control","status":"RECRUITING","sponsor":"Ruihua Wei","startDate":"2024-02-01","conditions":["Myopia"],"enrollment":410,"completionDate":"2026-03-31"},{"nctId":"NCT07129889","phase":"NA","title":"Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine","status":"NOT_YET_RECRUITING","sponsor":"Ningbo Eye Hospital","startDate":"2025-12-02","conditions":["Myopia"],"enrollment":180,"completionDate":"2027-06-30"},{"nctId":"NCT07120165","phase":"","title":"Effectiveness of Myopia Control Interventions : A Comparison of Myopia Control in European Children, Adolescents and Young Adults With Defocus Incorporated Multiple Segments (DIMS) and Highly Aspherical Lenslets (HAL) Spectacles, Atropine, Lenses and Combined Treatments","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2024-10-20","conditions":["Myopia"],"enrollment":114,"completionDate":"2025-05-07"},{"nctId":"NCT04315558","phase":"PHASE2","title":"Revefenacin in Acute Respiratory Insufficiency in COPD","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2020-11-01","conditions":["COPD","Acute Respiratory Failure"],"enrollment":21,"completionDate":"2025-01-01"},{"nctId":"NCT07092046","phase":"NA","title":"Minimal Flow Anesthesia and Infection Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ankara City Hospital Bilkent","startDate":"2025-07-01","conditions":["Minimal Flow Anesthesia","General Anaesthesia","Inhalation Anesthesia","Infection Risk","Anesthesia Circuit","Microbial Colonization","Anesthesia Equipment Bacterial Contamination"],"enrollment":140,"completionDate":"2026-01"},{"nctId":"NCT06209281","phase":"PHASE3","title":"A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-05-13","conditions":["Myopia"],"enrollment":526,"completionDate":"2025-12"},{"nctId":"NCT06209320","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-03-15","conditions":["Myopia"],"enrollment":777,"completionDate":"2025-08"},{"nctId":"NCT03909165","phase":"PHASE4","title":"Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-07-23","conditions":["Neuromuscular Blockade"],"enrollment":145,"completionDate":"2023-09-21"},{"nctId":"NCT07064434","phase":"NA","title":"Sacral Canal Block for Hip Replacement the Efficacy and Safety of Controlled Intraoperative Hypotension","status":"RECRUITING","sponsor":"General Hospital of Ningxia Medical University","startDate":"2024-11-01","conditions":["Postoperative Pain"],"enrollment":80,"completionDate":"2025-10-30"},{"nctId":"NCT06912048","phase":"NA","title":"Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2025-05-14","conditions":["Autonomic Function"],"enrollment":52,"completionDate":"2027-05"},{"nctId":"NCT03911271","phase":"PHASE2","title":"Low-dose Atropine for the Prevention of Myopia Progression in Danish Children","status":"COMPLETED","sponsor":"Line Kessel","startDate":"2019-05-30","conditions":["Myopia"],"enrollment":97,"completionDate":"2024-04-23"},{"nctId":"NCT03094052","phase":"PHASE2","title":"Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-10-09","conditions":["HER2-positive Breast Cancer","Breast Adenocarcinoma","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Stage IIIA Breast Cancer AJCC v7","Stage IIIB Breast Cancer AJCC v7","Stage IIIC Breast Cancer AJCC v7"],"enrollment":11,"completionDate":"2022-10-31"},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":["Rhegmatogenous Retinal Detachment"],"enrollment":168,"completionDate":"2027-01-30"},{"nctId":"NCT07033442","phase":"NA","title":"Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery","status":"COMPLETED","sponsor":"Ataturk Training and Research Hospital","startDate":"2015-07-23","conditions":["Anaesthesia","Intraocular Pressure","Trendelenburg Position","Robot Assisted Laparoscopic Radical Prostatectomy","Total Intravenous Anesthesia","Inhalation Anesthesia"],"enrollment":60,"completionDate":"2015-12-24"},{"nctId":"NCT07030153","phase":"","title":"Association of Genetic Variants With Myopia","status":"RECRUITING","sponsor":"Beijing Visionly Plus Eye Hospital","startDate":"2025-07-01","conditions":["Myopia"],"enrollment":1000,"completionDate":"2028-12-31"},{"nctId":"NCT06135896","phase":"PHASE2","title":"Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2024-01-16","conditions":["Unresectable Pancreatic Cancer","Unresectable Bile Duct Carcinoma","Unresectable Biliary Tract Carcinoma"],"enrollment":98,"completionDate":"2026-06-30"},{"nctId":"NCT06200194","phase":"PHASE2","title":"Early Intervention for Premyopic Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Yang Ming Chiao Tung University Hospital","startDate":"2024-10-06","conditions":["Myopia","Preschool"],"enrollment":240,"completionDate":"2026-07"},{"nctId":"NCT07016737","phase":"PHASE3","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ye jinjun","startDate":"2024-08-01","conditions":["Esophageal Squamous Cell Carcinoma (ESCC)"],"enrollment":79,"completionDate":"2029-09-01"},{"nctId":"NCT05666219","phase":"PHASE4","title":"Reversal of Complete Heart Block With Aminophylline in Inferior Wall Myocardial Infarction Patients","status":"WITHDRAWN","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2022-12-19","conditions":["Complete Heart Block","Inferior Wall Myocardial Infarction"],"enrollment":0,"completionDate":"2025-01-17"},{"nctId":"NCT05644873","phase":"NA","title":"Intravenous Administration of Magnesium Sulfate in Hysterectomy Cases","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2023-11-15","conditions":["Abdominal Hysterectomy","General Anesthesia","Magnesium Sulfate"],"enrollment":48,"completionDate":"2024-04-30"},{"nctId":"NCT06982092","phase":"PHASE1","title":"Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine.","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-08-26","conditions":["Perioperative Diaphragmatic Function"],"enrollment":60,"completionDate":"2025-01-15"},{"nctId":"NCT06922097","phase":"NA","title":"Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements","status":"RECRUITING","sponsor":"University of Hamburg-Eppendorf","startDate":"2025-04-07","conditions":["Intraoperative Bradycardia"],"enrollment":186,"completionDate":"2026-02"},{"nctId":"NCT03140358","phase":"PHASE3","title":"The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Singapore National Eye Centre","startDate":"2017-04-21","conditions":["Myopia"],"enrollment":300,"completionDate":"2025-12-31"},{"nctId":"NCT06970574","phase":"NA","title":"Comparative Study Between Intrathecal (Dexmedetomidine Versus Fentanyl)","status":"COMPLETED","sponsor":"Sohag University","startDate":"2022-07-10","conditions":["Cholecystitis"],"enrollment":60,"completionDate":"2023-07-10"},{"nctId":"NCT05786950","phase":"NA","title":"Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2023-01-01","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":44,"completionDate":"2024-09-01"},{"nctId":"NCT06683911","phase":"","title":"Opioids Continue to Play a Primary Role in the Management of Perioperative Pain Due to Opioid-Free Anesthesia in Open Heart Surgery.","status":"COMPLETED","sponsor":"Ankara City Hospital Bilkent","startDate":"2024-04-03","conditions":["Undergoing Open-Heart Surgery"],"enrollment":98,"completionDate":"2025-04-03"},{"nctId":"NCT06074185","phase":"PHASE2","title":"Treating Respiratory Emergencies in Children Study","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2024-02-19","conditions":["Asthma in Children"],"enrollment":44,"completionDate":"2025-03-11"},{"nctId":"NCT05667454","phase":"PHASE3","title":"MAD Trial: Myopia Atropine Dose","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2022-12-19","conditions":["Progressive Myopia"],"enrollment":550,"completionDate":"2029-04-01"},{"nctId":"NCT06918418","phase":"PHASE4","title":"A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children","status":"COMPLETED","sponsor":"Children's Hospital and Institute of Child Health, Multan","startDate":"2024-01-01","conditions":["Asthma Exacerbation","Children"],"enrollment":60,"completionDate":"2024-07-15"},{"nctId":"NCT05724550","phase":"NA","title":"Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2023-02-22","conditions":["Neuromuscular Block, Residual"],"enrollment":73,"completionDate":"2024-06-08"},{"nctId":"NCT06436768","phase":"NA","title":"Efficacy and Safety of Sugammadex in Thoracoscopy Thymectomy for Chinese Adults With Myasthenia Gravis","status":"COMPLETED","sponsor":"Beijing Tongren Hospital","startDate":"2024-06-01","conditions":["Reversal of Neuromuscular Blockade"],"enrollment":62,"completionDate":"2025-03-05"},{"nctId":"NCT06275542","phase":"NA","title":"Ability to Maintain Saturation Levels Without Oxygen Supplementation as a Extubation Criteria Without TOF Monitoring Equipment","status":"ENROLLING_BY_INVITATION","sponsor":"University of Surabaya","startDate":"2024-04-01","conditions":["Anesthesia Intubation Complication"],"enrollment":240,"completionDate":"2026-01-01"},{"nctId":"NCT06389110","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-03-15","conditions":["Myopia","Myopia, Progressive"],"enrollment":123,"completionDate":"2027-10-30"},{"nctId":"NCT05411159","phase":"NA","title":"Effect of Opioid-free Anesthesia on PostOperative Nausea and Vomiting in Patients Undergoing Video-assisted Thoracoscopic Surgery","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2022-06-07","conditions":["Postoperative Nausea and Vomiting","Opioid Use","Thoracic Diseases"],"enrollment":168,"completionDate":"2024-11-30"},{"nctId":"NCT04252989","phase":"","title":"Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2019-12-18","conditions":["Myopia","Children"],"enrollment":50,"completionDate":"2027-12"},{"nctId":"NCT03865160","phase":"PHASE2,PHASE3","title":"Low-dose Atropine for Myopia Control in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Eye Hospital, Freiburg","startDate":"2021-10-19","conditions":["Myopia, Progressive"],"enrollment":302,"completionDate":"2027-11"},{"nctId":"NCT06836999","phase":"NA","title":"Deep Sedation in Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2025-03-03","conditions":["Atrial Fibrillation","Atrial Fibrillation, Paroxysmal or Persistent","Deep Sedations","Conscious Sedation"],"enrollment":1334,"completionDate":"2027-12-31"},{"nctId":"NCT06764667","phase":"NA","title":"Comparison of Spinal Anesthesia Adjuvant and Quadratus Lumborum Block on the Opioid Requirement and Perioperative Pain of Laparoscopic Kidney Transplant Donor","status":"RECRUITING","sponsor":"Indonesia University","startDate":"2025-02-10","conditions":["Laparoscopic Donor Nephrectomy","Perioperative Pain Management"],"enrollment":60,"completionDate":"2026-01-31"},{"nctId":"NCT06667037","phase":"NA","title":"Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control","status":"RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-09-21","conditions":["Myopia"],"enrollment":194,"completionDate":"2027-03-31"},{"nctId":"NCT05379855","phase":"NA","title":"A-eyedrops on Ocular Alignment and Binocular Vision","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-03-02","conditions":["Exotropia","Exophoria","Myopia"],"enrollment":339,"completionDate":"2027-02-01"},{"nctId":"NCT05662371","phase":"NA","title":"Influence of Nociception Level Monitor (NOL) Guided Analgesic Delivery on Robot-assisted Colorectal Surgery","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2023-08-01","conditions":["Opioid Use, Unspecified","Pain, Postoperative"],"enrollment":60,"completionDate":"2025-12-31"},{"nctId":"NCT06824025","phase":"EARLY_PHASE1","title":"Comparison of Nebulized Neostigmine/Atropine Versus Lignocaine in Treating Acute Post-dural Puncture Headache Following Subarachnoid Block in Parturient Undergoing Elective Cesarean Section. A Randomized, Clinical Trial.","status":"NOT_YET_RECRUITING","sponsor":"Minia University","startDate":"2025-02-20","conditions":["Post-Dural Puncture Headache"],"enrollment":111,"completionDate":"2027-01-05"},{"nctId":"NCT06657079","phase":"PHASE1,PHASE2","title":"A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing ARDS","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2024-05-01","conditions":["ARDS","Prevention and Control"],"enrollment":119,"completionDate":"2025-01-01"},{"nctId":"NCT06794450","phase":"PHASE1,PHASE2","title":"Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade","status":"RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2024-11-05","conditions":["Neuromuscular Blocking Agents","Reversal of Neuromuscular Blockade","Recovery Time"],"enrollment":60,"completionDate":"2025-02"},{"nctId":"NCT06787638","phase":"PHASE1","title":"Effects of Neostigmine-dose on Diaphragmatic Dynamics","status":"NOT_YET_RECRUITING","sponsor":"Aswan University Hospital","startDate":"2025-01-25","conditions":["Diaphragm Ultrasound"],"enrollment":50,"completionDate":"2026-04"},{"nctId":"NCT06765603","phase":"PHASE2","title":"Evaluating the Efficacy of the Combination of Multi-zonal Contact Lens and Atropine for Controlling Myopia Progression","status":"NOT_YET_RECRUITING","sponsor":"Singapore National Eye Centre","startDate":"2025-02-01","conditions":["Myopia"],"enrollment":180,"completionDate":"2029-12-31"},{"nctId":"NCT03942419","phase":"PHASE3","title":"Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression","status":"TERMINATED","sponsor":"Eyenovia Inc.","startDate":"2019-06-03","conditions":["Myopia"],"enrollment":438,"completionDate":"2024-11-20"},{"nctId":"NCT06708156","phase":"PHASE3","title":"The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression","status":"RECRUITING","sponsor":"Oupushifang Pharmaceutical Technology Co., Ltd.","startDate":"2024-06-15","conditions":["Myopia","Myopia Progression"],"enrollment":606,"completionDate":"2027-12-31"},{"nctId":"NCT05164367","phase":"EARLY_PHASE1","title":"Pharmacokinetics of Atropine Oral Gel","status":"COMPLETED","sponsor":"University of Utah","startDate":"2022-10-01","conditions":["Cerebral Palsy","Sialorrhea"],"enrollment":10,"completionDate":"2024-12-10"},{"nctId":"NCT04016246","phase":"PHASE3","title":"Respiratory Effect of the LISA Method with Sedation by Propofol Versus Absence of Sedation.","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2019-10-07","conditions":["Respiratory Distress Syndrome in Premature Infant"],"enrollment":233,"completionDate":"2026-10"},{"nctId":"NCT06034379","phase":"NA","title":"Electronic Spectacles Versus Low Dose Atropine in Young Myopes","status":"RECRUITING","sponsor":"Kubota Vision Inc.","startDate":"2023-10-01","conditions":["Myopia"],"enrollment":45,"completionDate":"2025-12"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Elixir, Injection","formulations":[{"form":"ELIXIR","route":"ORAL","productName":"Donnatal"},{"form":"ELIXIR","route":"ORAL","productName":"Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide"},{"form":"ELIXIR","route":"ORAL","productName":"Phenohytro"},{"form":"ELIXIR","route":"ORAL","productName":"QUADRAPAX"},{"form":"ELIXIR","route":"ORAL","productName":"RE-PB HYOS ELIXIR"},{"form":"ELIXIR","route":"ORAL","productName":"Donnatal"},{"form":"ELIXIR","route":"ORAL","productName":"PHENOBARBITAL WITH BELLADONNA ALKALOIDS"},{"form":"ELIXIR","route":"ORAL","productName":"Phenobarbital with Belladonna Alkaloids - Grape"},{"form":"ELIXIR","route":"ORAL","productName":"Phenobarbital with Belladonna Alkaloids - Mint"},{"form":"INJECTION","route":"ENDOTRACHEAL","productName":"ATROPINE SULFATE"},{"form":"INJECTION","route":"ENDOTRACHEAL","productName":"Atropine Sulfate"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"ATROPEN Auto-Injector"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"N/A"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"ATROPINE SULFATE"},{"form":"INJECTION","route":"INTRAMUSCULAR","productName":"Atropine Sulfate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147687","MMSL":"27333","NDDF":"001715","UNII":"7C0697DR9I","VUID":"4019591","CHEBI":"CHEBI:16684","VANDF":"4017410","RXNORM":"1223","UMLSCUI":"C0004259","chemblId":"CHEMBL4557433","ChEMBL_ID":"CHEMBL2146146","KEGG_DRUG":"D00113","DRUGBANK_ID":"DB00572","PDB_CHEM_ID":" OIN","PUBCHEM_CID":"174174","SNOMEDCT_US":"372832002","IUPHAR_LIGAND_ID":"320","SECONDARY_CAS_RN":"5908-99-6","MESH_DESCRIPTOR_UI":"D001285"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1960-","companyName":"Gd Searle Llc","relationship":"Original Developer"},{"period":"present","companyName":"Mmt","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.1 hours","clearance":"7.6 mL/min/kg","bioavailability":"50%","fractionUnbound":"0.61%","volumeOfDistribution":"3.3 L/kg"},"publicationCount":32168,"therapeuticAreas":["Ophthalmology"],"atcClassification":{"source":"DrugCentral","atcCode":"A03BA01","allCodes":["A03BA01","A03CB03","S01FA01"]},"biosimilarFilings":[],"originalDeveloper":"Gd Searle Llc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Abbvie"],"status":"approved","companyName":"Mmt","companyId":"mmt","modality":"Small molecule","firstApprovalDate":"1960","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"refused","approval_date":null,"mah":null,"brand_name_local":"Atropine sulfate FGK","application_number":"EMEA/H/C/006385"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Atropine sulfate FGK","application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":12,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:21:14.102954+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}